Summit signs zebrafish platform deal with J&J
UK biotechnology company Summit has signed a non-exclusive research agreement with US health care giant Johnson & Johnson to explore and develop the use of zebrafish screening in drug discovery and development.
Under the terms of the agreement, Summit will receive an undisclosed amount over three years to support the development of new assays using the zebrafish platform., which is used to screen drug candidates for a broad range of toxicity and safety issues.
The research will be undertaken at a new state-of-the-art facility in Singapore and will be established and maintained by Summit. The latter expects the facility in Singapore to be fully operational early in 2009, when it will undertake primary assay development work in accordance with the agreement. In addition, Summit will use Singapore as a base to target new markets in the Far East and expand its current zebrafish screening services business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze